Boehringer, Eli Lilly to develop diabetes compounds
The compounds are Boehringer Ingelheim‘s two oral diabetes agents – linagliptin and BI10773 as well as Lilly‘s two basal insulin analogues – LY2605541 and LY2963016. The agreement also
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.